NovoCure Competitors

NovoCure (NASDAQ:NVCR) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for NovoCure and Boston Scientific, as provided by MarketBeat.com.

NovoCure presently has a consensus target price of $126.00, indicating a potential downside of 27.22%. Boston Scientific has a consensus target price of $42.7826, indicating a potential upside of 8.23%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than NovoCure.

Profitability

This table compares NovoCure and Boston Scientific's net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 90.7% of Boston Scientific shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 0.7% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares NovoCure and Boston Scientific's top-line revenue, earnings per share and valuation.

Boston Scientific has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Summary

Boston Scientific beats NovoCure on 11 of the 15 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 82.9% of Baxter International shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 0.1% of Baxter International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for NovoCure and Baxter International, as provided by MarketBeat.com.

NovoCure presently has a consensus target price of $126.00, indicating a potential downside of 27.22%. Baxter International has a consensus target price of $92.2667, indicating a potential upside of 17.52%. Given Baxter International's stronger consensus rating and higher possible upside, analysts clearly believe Baxter International is more favorable than NovoCure.

Profitability

This table compares NovoCure and Baxter International's net margins, return on equity and return on assets.

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Earnings & Valuation

This table compares NovoCure and Baxter International's top-line revenue, earnings per share and valuation.

Baxter International has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Summary

Baxter International beats NovoCure on 10 of the 14 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 94.1% of DexCom shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 0.7% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NovoCure and DexCom, as provided by MarketBeat.com.

NovoCure currently has a consensus target price of $126.00, indicating a potential downside of 27.22%. DexCom has a consensus target price of $430.3750, indicating a potential upside of 6.10%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than NovoCure.

Profitability

This table compares NovoCure and DexCom's net margins, return on equity and return on assets.

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, DexCom has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and DexCom's top-line revenue, earnings per share and valuation.

DexCom has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Summary

DexCom beats NovoCure on 10 of the 14 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 68.6% of ResMed shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 1.3% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NovoCure and ResMed, as provided by MarketBeat.com.

NovoCure currently has a consensus target price of $126.00, indicating a potential downside of 27.22%. ResMed has a consensus target price of $189.40, indicating a potential downside of 5.76%. Given ResMed's stronger consensus rating and higher possible upside, analysts plainly believe ResMed is more favorable than NovoCure.

Profitability

This table compares NovoCure and ResMed's net margins, return on equity and return on assets.

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and ResMed's top-line revenue, earnings per share and valuation.

ResMed has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Summary

ResMed beats NovoCure on 8 of the 13 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and Teleflex (NYSE:TFX) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. Comparatively, 89.8% of Teleflex shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 2.2% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NovoCure and Teleflex, as provided by MarketBeat.com.

NovoCure currently has a consensus target price of $126.00, indicating a potential downside of 27.22%. Teleflex has a consensus target price of $421.2727, indicating a potential upside of 5.22%. Given Teleflex's stronger consensus rating and higher possible upside, analysts plainly believe Teleflex is more favorable than NovoCure.

Profitability

This table compares NovoCure and Teleflex's net margins, return on equity and return on assets.

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and Teleflex's top-line revenue, earnings per share and valuation.

Teleflex has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Summary

Teleflex beats NovoCure on 11 of the 15 factors compared between the two stocks.

NovoCure (NASDAQ:NVCR) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

71.1% of NovoCure shares are owned by institutional investors. 5.1% of NovoCure shares are owned by company insiders. Comparatively, 1.1% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NovoCure and Insulet, as provided by MarketBeat.com.

NovoCure currently has a consensus target price of $126.00, indicating a potential downside of 27.22%. Insulet has a consensus target price of $243.0556, indicating a potential downside of 7.36%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than NovoCure.

Profitability

This table compares NovoCure and Insulet's net margins, return on equity and return on assets.

Volatility & Risk

NovoCure has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Insulet has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Earnings and Valuation

This table compares NovoCure and Insulet's top-line revenue, earnings per share and valuation.

Insulet has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Summary

NovoCure beats Insulet on 8 of the 14 factors compared between the two stocks.